For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > REGULATORY
REGULATORY
- Early Approval, Reimbursement of SaMD Put on Priority Agenda: Deregulation Panel
October 25, 2022
- Japan Might Change Timing of Drug Price Revisions from April amid Medical DX Push
October 24, 2022
- Nearly 700 Key Drugs Found to Be Unprofitable Due to Inflation, FX: Survey
October 24, 2022
- Is New Expert Panel All about Drug Pricing System? Asks Chair
October 24, 2022
- Experts Call for Debate on Scope of Health Coverage, “Exit Rule” for Unnecessary Meds
October 24, 2022
- PMDA Reviewing New Safety Risks for Evrenzo and More Drugs
October 24, 2022
- With Shortened Interval, Omicron Booster Likely to Cover 18 Million More People by Month-End
October 21, 2022
- LDP Project Team to Present Proposal for FY2023 Drug Price Revision and Budget Planning
October 21, 2022
- COVID Booster Interval to Be Shortened to “At Least 3 Months”
October 20, 2022
- Silgard 9’s Label Updated to Add Long-Term Follow-Up Study Data
October 19, 2022
- Avigan Secured for COVID-19 to Be Stockpiled for Pandemic Flu: Health Minister
October 19, 2022
- Label Expansions for TS-1, Enhertu on PAFSC Agenda on Oct. 31
October 18, 2022
- Japan Panel Recognizes One More Death Possibly Linked to COVID Jab
October 18, 2022
- Health Ministry Research Team to Vet Recall Rules to Address Supply Disruptions
October 17, 2022
- Include COVID Drug R&D Support in New Economic Package: LDP Health Panel
October 17, 2022
- Pfizer’s Precedex Up for PAFSC Review for Pediatric Indication as Japan’s 1st “Specific Use Drug” on Oct. 28
October 17, 2022
- Japan to Prepare Schedule for DX in Medical Fee Revisions by Next Spring
October 14, 2022
- Lawmakers Call for Starting 9-Valent HPV Vaccination Program in April 2023
October 14, 2022
- Contraindication Lifted for Parmodia in Renal Impairment Patients
October 14, 2022
- Japan Looks to Secure 950,000 Courses of Lagevrio by Year-End amid Twindemic Threat
October 14, 2022
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…